|
|
| A Full-Service Solution Partner Disrupting the Outsourcing Paradigm | inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them. |
|
|
|
|
A conversation with James Graham, CEO, Recce Pharmaceuticals | Automation and the underlying chemistry of its R327 candidate have helped the antibiotic developer reach notably high production volumes. |
|
|
|
|
| Study, Not Software: Aligning RTSM To The Protocol | Article | By James Stringer, Signant Health | How can Randomization and Trial Supply Management (RTSM) platforms improve your clinical trial and how do they integrate with your other crucial trial systems? |
|
|
| Adapting Drug Supply Strategies To Modern Study Models | Article | Parexel International | Advancements like remote-access drug refrigerators and smart packaging highlight the need for patient-centric trial models that integrate virtual and site-based activities to meet diverse patient needs. |
|
|
|
|
|
.png){kind=logo}
